Adaptation of HIV-1 envelope gp120 to humoral immunity at a population level.
By comparing HIV-1 variants from people who became infected at the beginning of the epidemic and from people who have recently contracted the virus, we observed an enhanced resistance of the virus to antibody neutralization over time, accompanied by an increase in the length of the variable loops and in the number of potential N-linked glycosylation sites on the HIV-1 envelope gp120 subunit. The enhanced neutralization resistance of HIV-1 in contemporary seroconverters coincided with the poorer elicitation of neutralizing antibody responses, which may have implications for vaccine design.
Bunnik
Evelien M
EM
Department of Experimental Immunology, Sanquin Research, Landsteiner Laboratory, Center for Infection and Immunity Amsterdam, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Euler
Zelda
Z
Welkers
Matthijs R A
MR
Boeser-Nunnink
Brigitte D M
BD
Grijsen
Marlous L
ML
Prins
Jan M
JM
Schuitemaker
Hanneke
H
D016915:AIDS Vaccines / Q000276:immunology* / Q000627:therapeutic use; D000917:Antibody Formation / Q000276:immunology; D014644:Genetic Variation; D006678:HIV / Q000235:genetics / Q000276:immunology; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000235:genetics / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology*; D006801:Humans; D056724:Immunity, Humoral; D016756:Immunoglobulins, Intravenous / Q000276:immunology / Q000627:therapeutic use; D009500:Neutralization Tests; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology / Q000378:metabolism
D016915:AIDS Vaccines; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; C084715:HIV hyperimmune globulin; D016756:Immunoglobulins, Intravenous; D014759:Viral Envelope Proteins; C514793:gp120 protein, Human immunodeficiency virus 1
Nature. 2009 Apr 2;458(7238):641-5
19242411
Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4144-9
12644702
J Infect Dis. 2010 Apr 1;201(7):1045-53
20170371
J Virol. 2008 Aug;82(16):7932-41
18524815
J Infect Dis. 1997 Feb;175(2):283-91
9203648
J Virol. 2008 Nov;82(22):11054-65
18768967
Nature. 2003 Mar 20;422(6929):307-12
12646921
J Virol. 1997 Oct;71(10):7719-27
9311856
Proc Natl Acad Sci U S A. 2008 May 27;105(21):7552-7
18490657
J Virol. 2007 Jun;81(12):6187-96
17409164
J Exp Med. 2009 Jun 8;206(6):1273-89
19487424
J Virol. 2006 Oct;80(19):9586-98
16973562
J Virol. 2004 May;78(10):5205-15
15113902
J Virol. 2007 Feb;81(3):1350-9
17079307